The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

New data from over 15 million people in Canada shows weight management drugs climbing 90.6 per cent since 2023; diabetes drugs hold top spot; biosimilar adoption up more than 27 per cent.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

While there is not currently a shortage of Ozempic, previous difficulties in supplying this medication have led to some pharmacies offering compounded semaglutide. The Food and Drug Administration ...

New Delhi: In line with the proposal for approval of Semaglutide tablets 1.5 mg, 4 mg, 9 mg of new formulation based on the bioequivalence (BE) studies conducted in USA and Canada, the Subject Expert ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Conversely, Lilly's stock price jumped about 14.5% to $840. “While Novo had the headstart with approval of semaglutide, we believe that this first mover advantage has waned, with Lilly's ...

Although different active ingredients - Mounjaro is tirzepatide and Ozempic and Wegovy is semaglutide - they all work by mimicking hormones that tell the brain the stomach is full, releasing ...

If approved, orforglipron would offer an alternative to another GLP-1 pill, Rybelsus (semaglutide). That medication has been available by prescription since 2019 for the treatment of Type 2 ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New ...